MedPath

Prevention of Long Covid Syndrome

Not Applicable
Completed
Conditions
Quality of Life
Pain
Post-Acute COVID-19 Syndrome
Biofeedback, Psychology
Cognitive Symptom
Depressive Symptoms
Fatigue
Anxiety
Interventions
Device: Biofeedback training
Registration Number
NCT05793736
Lead Sponsor
University of Cagliari
Brief Summary

Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management in post-Covid-19 syndrome.

The main objective of the study is to verify the feasibility of an HVR biofeedback training protocol in patients with long covid, and also to verify improvement induced by the technique in relation to: cognitive performance; pain perception; fatigue; quality of life; depressive and anxious symptoms

Detailed Description

Long COVID is known by different names, and include a wide range of persistent symptoms that develop after SARS-CoV-2 infection and last for usually more than 12 weeks to months and up to 2 years, so far. The most common symptoms categorizable as neurological are fatigue, brain fog, and headache, among respiratory symptoms chest pain and shortness of breath, other less easily classifiable symptoms are heart palpitations and muscle pain. These symptoms are often debilitating enough to leave patients unable to work.

According to the WHO (2023), an estimated 17 million people were thought to be living with the long-term effects of COVID-19. Still now in less active pandemic phases, the risk of developing long COVID symptoms, at 10-20% of those infected, remains just as strong.

Trying to find a solution to manage symptoms through evidence-based practices is considered a current necessity to help health patients and professionals.

Biofeedback allows to learn self-regulation of some physiological processes through feedback of recorded parameters and the goal is improving health and its performances.

Biofeedback measures muscle activity, skin temperature, electrodermal activity (sudoriparous glands activity), respiration, heart rate, blood pressure, electrical brain activity and bloodstream, it also gives a quick feedback of those personal measurements to the patient, in this way biofeedback teaches people to have a more active role in maintaining a good personal, mental and physical health (quickly and thoroughly it give person feedback of activity and biofeedback teaches people to take a more active role in maintaining personal health and mental health and physical health).

Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management (evidence were shown as regards stress menagement).

The greatest benefits from using biofeedback are: improvement of sleep quality, improvement of self- efficacy, improvement of pain threshold, and improvement of emotional adjustment. In particular, a study conducted with HRV biofeedback, in which the sample learned resonance frequency breathing, showed dicreases in depression and pain and improved the person's system functioning.

Study objectives

The main objective of the study is to verify the feasibility of an HVR biofeedback training protocol in patients with Long Covid syndrome, and also to produce a preliminary measurement of the possible improvement induced by the technique in relation to:cognitive performance; pain perception; fatigue; quality of life; depressive and anxious symptoms. This measure will be useful to estimate the expected improvement in future case-control studies. Study design

This is a controlled clinical trial between usual care and biofeedback training plus usual care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • People who have contracted Covid-19 and have symptoms attributable to Long syndrome
Exclusion Criteria
  • patients with cognitive difficulties and/or diagnosis of mental retardation
  • patients with severe comorbidities with the exception of anxious/depression symptoms arising in conjunction with the viral infection or long covid syndrome.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
treatment as usualTreatment as usualThe control sample (n 10) will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
biofeedback + treatment as usualBiofeedback trainingThe selected sample (n 10) will undergo 10 total Biofeedback Training sessions, twice a week. Each session will last 45 minutes. The total duration of the treatment will be 5 weeks, plus standard therapies (treatment as usual)
Primary Outcome Measures
NameTimeMethod
Change from Baseline to 5 weeks and to 9 weeks in Brief Fatigue Inventory (BFI) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

The Brief Fatigue Inventory (BFI) is a brief screening tool designed to assess the severity and impact of fatigue on daily functioning.

Change from Baseline to 5 weeks and to 9 weeks in Visual Analog Scale VAS (Scott Huskisson, 1976) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Allows you to have a visual representation of the amplitude of the pain perceived by the person ache

Change from Baseline to 5 weeks and to 9 weeks in Digit Span (Orsini et al., 1987; Mondini et al., 2003) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Evaluate verbal short-term memory and working memory

Change from Baseline to 5 weeks and to 9 weeks in Frontal Assessment Battery - FAB (Dubois et al.; 2000) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

It is a functionality screening battery global executive performance by means of a series of cognitive and behavioral tests

Intervention satisfaction questionnaireT1 (5weeks)

Intervention satisfaction questionnaire

Change from Baseline to 5 weeks and to 9 weeks in Patient Health Questionnaire-9 (PHQ-9) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

short self-administered tool used for screening, diagnosis, monitoring and measuring the severity of depression. It's composed of 9 items that correspond to the symptoms of major depression according to DSM-IV. The score has a range between 0 and 27. Scores between 0 and 9 indicate the presence of a sub-threshold depression. The score of 10 is indicated as the point at which the sensitivity and specificity of the instrument are recognized as optimal for highlighting depressions of clinical relevance

Change from Baseline to 5 weeks and to 9 weeks in Self-Rating Anxiety Scale (SAS) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

SAS is a 20-item self-report assessment device built to measure anxiety levels, based on scoring in 4 groups of manifestations: cognitive, autonomic, motor and central nervous system symptoms.

Change from Baseline to 5 weeks and to 9 weeks in Short Form Health Survey (SF-12) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

The Short Form Health Survey (SF-12), brief version of SF-36 questionnaire, made up of twelve questions, includes the following dimensions: physical activity, disturbance in physical health, physical condition, self-assessment of health status, vitality, social activity and mental health. Higher SF-12 scores recorded a greeting and QoL performance.

Change from Baseline to 5 weeks and to 9 weeks in Trail Making Test (Giovagnoli et al.,1996) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Evaluates cognitive functions such as cognitive flexibility and inhibitory control and attention

Change from Baseline to 5 weeks and to 9 weeks in Matrix test (Spinnler H, Tognoni G., 1987) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Evaluates the indicators of selective attention

Change from Baseline to 5 weeks and to 9 weeks in Stroop Test (Caffarra et al.; 2002) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Evaluates selective attention, the processes of inhibition of irrelevant information and cognitive flexibility

Change from Baseline to 5 weeks and to 9 weeks in Rey's Word Test (Caltagirone et al. 1995) scoreT0 (0 weeks); T1 (5weeks); T2 (9 weeks)

Evaluates long-term memory, semantic memory, specifies in which phase of the mnemonic process the deficit is

Change in Checklist on tolerability, possible side effects after the biofeedback sessionAt the end of each biofeedback session

Checklist on tolerability, possible side effects after the biofeedback session

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

P.O. San Giovanni di Dio, AOU Cagliari

🇮🇹

Cagliari, Italy

© Copyright 2025. All Rights Reserved by MedPath